Stay tuned for a refresh of our website in early 2019. We’re certain you will like it!
WHO WE ARE
ALK Positive is made up of patients/survivors (ALK Positives) and their caregivers. Three tenets we live by are Information, Support, and Empathy, no matter where you may be. We uphold these by providing Worldwide Information about ALK-positive lung cancer to each other. We Support one another around the globe to improve our physical and emotional wellbeing; and having Empathy towards each other because we are all on this journey together, no matter where we live.
WHAT IS ALK-POSITIVE LUNG CANCER?
Anaplastic Lymphoma Kinase (ALK), the simplest explanation, is a genetic mutation/rearrangement of the ALK gene in the human body, which causes a malfunction that produces cancerous cells. There are several resources on the Internet to explain it in more detail. Here is one:
If you are an ALK-positive lung cancer patient/survivor, or the caregiver of an ALK-positive lung cancer patient/survivor, please go to our Facebook support group and request to join (ensure you answer the three questions). Come join and connect with your ALK Positive family. If you’re not either of the above but still wish to support the financial goals of our fundraising efforts, please click the DONATE NOW button below.
Our first three research grants have been awarded! See the post here.
MAKING TOMORROW A BRIGHTER DAY
ALK Positive members – survivors and caregivers alike – are committed to raising funds for research to increase ALK positive lung cancer patients’ survivability. The funds we raise will be used to fund research grants so researchers may continue to work towards making ALK lung cancer, as a minimum, a chronic illness while staying focused on a cure for lung cancer altogether. ALK Positive patients help each other through patient-driven fundraising for research.
We are partnering with LUNGevity to raise funds for ALK research. Our goal is to fund research proposals that seek to overcome or prevent the mechanisms of resistance that develop with all targeted therapies. By overcoming resistance, or preventing it in the first place, we hope to transform ALK positive lung cancer into a chronic condition for all patients living with this disease. This is the first time ALK patients will actually be able to influence the direction of research that will, one day, save their lives.
